Syntaxin & Ipsen Ink Botulinum Therapeutic Pact

Syntaxin will be responsible for the discovery of new therapeutic candidates and Ipsen will apply its pharmacological, preclinical and clinical assessments of the discovered compounds.

French pharmaceutical company Ipsen and UK-based biopharmaceutical company Syntaxin have established a global strategic collaboration for the discovery and development of new compounds in the field of botulinum toxins. 

Under the collaboration agreement, Syntaxin will be responsible for the discovery of new therapeutic candidates and Ipsen will apply its pharmacological, preclinical and clinical assessments of the discovered compounds.

Syntaxin is eligible to receive a technology access fee, employee support, and research milestones totaling $9 million in the first three years of the collaboration. Syntaxin is also eligible to receive additional license fees, development and regulatory milestones and potentially more than $90 million of commercial m